Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Xian-bin Liang"'
Autor:
Lei Lei, Wen-xian Wang, Zong-yang Yu, Xian-bin Liang, Wei-wei Pan, Hua-fei Chen, Li-ping Wang, Yong Fang, Min Wang, Chun-wei Xu, Mei-yu Fang
Publikováno v:
Translational Oncology, Vol 13, Iss 2, Pp 329-335 (2020)
BACKGROUND: KRAS gene mutations are well known as a key driver of advanced non–small cell lung cancer (NSCLC). The impact of KRAS-mutant subtypes on the survival benefit from salvage chemotherapy is controversial. Here, we present a real-world stud
Externí odkaz:
https://doaj.org/article/8735d400c9f345c390e3a3ece24e3adf
Autor:
Xian-bin Liang, Zhengbo Song, Liping Wang, Zongyang Yu, Chunwei Xu, Xingxiang Pu, Wenxian Wang, Huafei Chen, Jinluan Li, Yinbin Zhang, Tianle Shen
Publikováno v:
Clinical lung cancer. 21(5)
Background Rearranged during transfection (RET) proto-oncogene gene fusions are rare in non–small-cell lung cancer (NSCLC). We compared the efficacy of pemetrexed-based chemotherapy with other chemotherapy regimens in patients with NSCLC with diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7492485a16db268d63419b6f8347ff0
https://pubmed.ncbi.nlm.nih.gov/32143967
https://pubmed.ncbi.nlm.nih.gov/32143967
Autor:
You-cai Zhu, Hong Wang, Xin Liu, Rong-bo Lin, Mei‐yu Fang, Xiao-jia Wang, Liping Wang, Yinbin Zhang, Bing Wan, Tangfeng Lv, Xiuyu Cai, Li Lin, Yong Song, Xingxiang Pu, Shi-jie Lan, Xin Cai, Chunwei Xu, Wenxian Wang, Lei Lei, Wu Zhuang, Yong Fang, Gang Chen, Zongyang Yu, Jinluan Li, Zi-yan Yang, Xian-bin Liang
Publikováno v:
Cancer Research. 80:38-38
Background: NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 are oncogenic drivers of various solid tumor types but generally at a low frequency. TRK inhibitors such as LOXO-101, entrectinib, X396, AB-106, TL118 had remarkable and durable ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d8997061a0b3619654325468ca4088c
https://doi.org/10.1158/1538-7445.am2020-38
https://doi.org/10.1158/1538-7445.am2020-38
Autor:
Xiao-jia Wang, Ling Lin, Bing Wan, Yinbin Zhang, Liping Wang, Li Lin, Hong Wang, Tangfeng Lv, Yong Fang, Jian-ying Li, Xian-bin Liang, Wenxian Wang, Meiyu Fang, You-cai Zhu, Quxia Zhang, Xingxiang Pu, Shi-jie Lan, Yong Song, Wu Zhuang, Chunwei Xu, Xiu-yu Cai, Gang Chen, Yu Chen, Zongyang Yu, Xin Liu
Publikováno v:
Cancer Research. 79:1597-1597
Background: Recently, kinase domain duplications (KDD) in BRAF, EGFR, MET and FGFR1 were reported, along with responses to tyrosine kinase inhibitors (TKI). However, its frequency and clinical outcomes in advanced cancer patients are larglely uncerta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1fb9a4199ca7642f6b6bd9af3e86cad
https://doi.org/10.1158/1538-7445.am2019-1597
https://doi.org/10.1158/1538-7445.am2019-1597